167 related articles for article (PubMed ID: 33740172)
21. Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Zhang Z; Wang Y; Chen J; Tan Q; Xie C; Li C; Zhan W; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1289-1296. PubMed ID: 27832326
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling.
Li S; Liu X; Chen X; Zhang L; Wang X
Tumour Biol; 2015 Dec; 36(12):9661-5. PubMed ID: 26150340
[TBL] [Abstract][Full Text] [Related]
23. Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells.
Hazane-Puch F; Arnaud J; Trocmé C; Faure P; Laporte F; Champelovier P
Anticancer Agents Med Chem; 2016; 16(4):490-500. PubMed ID: 26286659
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
25. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
26. Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Tang Y; Ma J
J Exp Clin Cancer Res; 2018 Oct; 37(1):241. PubMed ID: 30285808
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells.
Imesch P; Samartzis EP; Dedes KJ; Fink D; Fedier A
Fertil Steril; 2013 Sep; 100(3):770-6. PubMed ID: 23755949
[TBL] [Abstract][Full Text] [Related]
28. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.
Chen J; Luo B; Wen S; Pi R
Invest New Drugs; 2020 Jun; 38(3):755-764. PubMed ID: 31414267
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
31. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
32. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.
Avril T; Vauleon E; Hamlat A; Saikali S; Etcheverry A; Delmas C; Diabira S; Mosser J; Quillien V
Brain Pathol; 2012 Mar; 22(2):159-74. PubMed ID: 21790828
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
34. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
35. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
36. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
37. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
38. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Silber J; Lim DA; Petritsch C; Persson AI; Maunakea AK; Yu M; Vandenberg SR; Ginzinger DG; James CD; Costello JF; Bergers G; Weiss WA; Alvarez-Buylla A; Hodgson JG
BMC Med; 2008 Jun; 6():14. PubMed ID: 18577219
[TBL] [Abstract][Full Text] [Related]
39. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
40. HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells.
Wu AC; Yang WB; Chang KY; Lee JS; Liou JP; Su RY; Cheng SM; Hwang DY; Kikkawa U; Hsu TI; Wang CY; Chang WC; Chen PY; Chuang JY
J Exp Clin Cancer Res; 2022 Feb; 41(1):47. PubMed ID: 35109908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
